ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1790

Response Gene to Complement-32 Expression Is Upregulated in Lupus T Cells and Promotes Th17 Differentiation

Violeta Rus1, Vinh Nguyen1, Alexandru Tatomir1, Cornelia Cudrici2 and Horea Rus1, 1University of Maryland at Baltimore, Baltimore, MD, 2National Institute of Health, Bethesda, MD

Meeting: ACR Convergence 2024

Keywords: Systemic lupus erythematosus (SLE), T Cell, TH17 Cells

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: RGC (Response Gene to Complement)-32 is a cell cycle regulator expressed in normal tissues, tumors and a variety of cell lines.  RGC-32 plays a role in a variety of pathological processes such as carcinogenesis, metabolic disorders, angiogenesis, atherosclerosis, and autoimmunity. We have shown that RGC-32 exerts a proinflammatory role by promoting Th17 responses in vitro and enhances Th-17 mediated autoimmune diseases in vivo. Th17 pathway has been linked to human lupus including lupus glomerulonephritis (GN). We have shown that in an immune complex mediated model of glomerulonephritis, RGC-32 promoted the Th17 and Th1 dependent proinflammatory responses and the organ specific pathways of renal fibrosis. The expression of RGC-32 in human PBMC and whether RGC-32 plays a role in the Th17 differentiation pathway and in Th17 abnormalities in lupus patients has not yet been investigated. 

Methods: RGC-32 mRNA expression was first assessed with the BD Biosciences Clontech Autoimmune Disease Profiling Array spotted with cDNA from CD3+, CD19+ and CD14+ cells from 11 lupus patients and 12 controls. PBMC were obtained from 20 patients with lupus and 18 controls. RGC-32 mRNA expression was determined by RT-PCR in purified CD4+ T cells from healthy controls, stimulated under Th0, Th1, Th2, Th17 and Treg conditions. The effect of RGC-32 overexpression and silencing under Th17 conditions was determined by nucleofection. RGC-32 expression in T cells from patients and controls was evaluated by RT-PCR, western blot and flow cytometry.

Results: Using the Autoimmune Disease Profiling Array, mRNA expression of RGC-32 in healthy controls was highest in CD3+, followed by CD14+ and CD19+ cells. By western blot, RGC-32 protein was constitutively expressed in T cell lysates from normal controls at baseline and upregulated upon TCR stimulation. By intracellular staining RGC-32 was detected in both CD4+ and CD8+ T cells. RGC-32 mRNA expression in T cells from healthy controls was upregulated by TCR stimulation, TGFβ, a known inducer and activator of RGC-32 and by incubation with serum from lupus patients with high anti ds-DNA levels. RGC-32 translocated into nucleus upon TCR stimulation in the presence of TGFβ. In in vitro T cell differentiation assays, RGC-32 upregulation was more robust under Th17 (3.2 ± fold) and Treg (2.6 ± 0.8 fold) vs. Th1 (1.3 ± 0.4 fold) and Th2 (1.8 ± 0.1 fold) conditions. Overexpression or silencing of RGC-32 in CD4+ T cells upregulated, respectively downregulated IL-17A transcript levels and protein secretion. RGC-32 mRNA expression was increased in T cells from lupus patients (1.5 ± 0.38) compared to controls (0.5± 0.2).  By flow cytometry, both the proportion (30%± 8 vs 16%± 5) and MFI (200± 65 vs 120±35) of RGC-32+ T cells was significantly higher in lupus T cells vs controls.

Conclusion:  These results suggest that RGC-32 promotes the differentiation of human Th17 cells. Furthermore, T cells from patients with lupus exhibit increased expression of RGC-32 compared to controls. These data support the idea that RGC-32 signaling may enhance disease expression in SLE by promoting abnormalities in the Th17 pathway and provide a compelling rationale for further investigating the therapeutic potential of blocking RGC-32 in lupus.


Disclosures: V. Rus: None; V. Nguyen: None; A. Tatomir: None; C. Cudrici: None; H. Rus: None.

To cite this abstract in AMA style:

Rus V, Nguyen V, Tatomir A, Cudrici C, Rus H. Response Gene to Complement-32 Expression Is Upregulated in Lupus T Cells and Promotes Th17 Differentiation [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/response-gene-to-complement-32-expression-is-upregulated-in-lupus-t-cells-and-promotes-th17-differentiation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/response-gene-to-complement-32-expression-is-upregulated-in-lupus-t-cells-and-promotes-th17-differentiation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology